Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
– 100% protection against severe disease – Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19 – Efficacy against variants confirmed in U.K. and South Africa Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe […]
